Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arthur Weinstein

Showing results (41-50 of 47) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 47 results.
Arthritis and Rheumatism|August 31, 2012
Measurement of cell-bound complement activation products enhances diagnostic performance in systemic lupus erythematosusKenneth C Kalunian, W Winn Chatham, Elena M Massarotti, et al.
Lupus Science & Medicine|November 15, 2014
Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurementsChaim Putterman, Richard Furie, Rosalind Ramsey-Goldman, et al.
Seminars in Arthritis and Rheumatism|October 4, 2025
Discontinuation versus continuation of maintenance treatment with tumor necrosis factor inhibitors in patients with rheumatoid arthritis with low disease activity or remission: A randomized double-blind placebo-controlled trialMichael M Ward, Arthur Weinstein, Paloma Alejandro-Silva, et al.
Seminars in Arthritis and Rheumatism|February 24, 2004
High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learnedPhilip J Clements, James R Seibold, Daniel E Furst, et al.
Lupus Science & Medicine|May 7, 2020
Cell-bound complement activation products associate with lupus severity in SLECristina Arriens, Roberta Vezza Alexander, Sonali Narain, et al.
Arthritis and Rheumatism|October 2, 2002
Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenonPeter A Merkel, Karen Herlyn, Richard W Martin, et al.
Arthritis and Rheumatism|November 13, 2002
Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trialPaul J DeMarco, Michael H Weisman, James R Seibold, et al.
Pageof 5

Showing results (41-50 of 47) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 47 results.
Arthritis and Rheumatism|August 31, 2012
Measurement of cell-bound complement activation products enhances diagnostic performance in systemic lupus erythematosusKenneth C Kalunian, W Winn Chatham, Elena M Massarotti, et al.
Lupus Science & Medicine|November 15, 2014
Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurementsChaim Putterman, Richard Furie, Rosalind Ramsey-Goldman, et al.
Seminars in Arthritis and Rheumatism|October 4, 2025
Discontinuation versus continuation of maintenance treatment with tumor necrosis factor inhibitors in patients with rheumatoid arthritis with low disease activity or remission: A randomized double-blind placebo-controlled trialMichael M Ward, Arthur Weinstein, Paloma Alejandro-Silva, et al.
Seminars in Arthritis and Rheumatism|February 24, 2004
High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learnedPhilip J Clements, James R Seibold, Daniel E Furst, et al.
Lupus Science & Medicine|May 7, 2020
Cell-bound complement activation products associate with lupus severity in SLECristina Arriens, Roberta Vezza Alexander, Sonali Narain, et al.
Arthritis and Rheumatism|October 2, 2002
Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenonPeter A Merkel, Karen Herlyn, Richard W Martin, et al.
Arthritis and Rheumatism|November 13, 2002
Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trialPaul J DeMarco, Michael H Weisman, James R Seibold, et al.
Pageof 5